We have previously reported that r28M, a recombinant bispecific single-chain antibody directed to a melanoma-associated proteoglycan (NG2) and the costimulatory CD28 molecule on T cells, induced T-cell activation, which resulted in tumor-cell killing. T-cell activation did not require a primary signal through the T-cell antigen receptor (TCR)/CD3 complex and depended on the presence of NG2-positive tumor cells. Here, we further investigate this phenomenon of a target cell-restricted, supraagonistic CD28 stimulation with bispecific antibodies. To this end, we exchanged the NG2 targeting part of r28M with a singlechain antibody directed to the B-cell associated antigen CD20. The resulting bispecific single-chain antibody, termed r2820, induced supra-agonistic T-cell activation, which required the presence of autologous normal or malignant B cells, respectively. Once activated, T cells were capable of destroying lymphoma target cells.
Introduction
Together with the antigen-specific T-cell antigen receptor (TCR)/ CD3 complex, costimulatory receptors on T cells and their ligands, which are primarily expressed on antigen-presenting cells, regulate T-cell activation and thereby the course of a specific immune response. Thus, these molecules are attractive candidates for drug targeting. This is best illustrated by the B7 molecules on antigen-presenting cells which stimulate CD28 and CTLA on T cells, thereby delivering costimulatory and coinhibitory signals, respectively. Several recombinant proteins that interfere specifically with B7/CD28/CTLA4-mediated signaling have been developed for therapeutic stimulation as well as suppression of specific immunity. 1 In particular, 'superagonistic' CD28 antibodies have been described which induce potent T-cell activation without a primary TCR/CD3 stimulus. 2 It has been proposed to use such antibodies for the treatment of immunodeficiency states 3 as well as autoimmune diseases. 4 Recently however, one of these antibodies, TGN1412, induced a life-threatening cytokine release syndrome in six healthy volunteers. 5 This incident has dramatically illustrated that the activity of T-cell stimulating antibodies upon in vivo application must be tightly controlled. One way of achieving this is by the construction of bispecific antibodies which enable target cellrestricted rather than systemic T-cell stimulation.
We reported earlier on a bispecific single-chain antibody (bi-scFv) directed to a melanoma-associated proteoglycan (NG2) and to CD28, termed r28M, that is capable of inducing T-cell activation and effective tumor-cell killing in vitro and in vivo without a signal through the TCR/CD3 complex. [6] [7] [8] This supra-agonistic activity was dependent on binding of the antibody to NG2-positive melanoma cells and was thus target cell-restricted. The activity of r28M was unexpected in as much as the CD28 antibody used for construction of this molecule is an ordinary, costimulatory antibody without 'superagonistic' properties. A closer examination of r28M revealed that the supra-agonistic activity of the bispecific antibody resided mainly in spontaneously formed, stable dimeric versions of the molecule. 6 In all of the experiments mentioned above, the tumor cells used as targets and the effector T cells were obtained from different donors and we could not rule out entirely that allogeneic effects contributed to the supra-agonistic CD28 stimulation mediated by r28M. Furthermore, we wanted to exclude the possibility that this phenomenon is unique for the r28M molecule. To this end, we exchanged the NG2 targeting part of r28M with a single-chain antibody directed to the B cellassociated antigen CD20, a well-established target antigen on lymphoma cells of the B-cell lineage. The resulting bispecific single-chain antibody with CD28 Â CD20-specificity, r2820, enabled us to set up a series of experiments using autologous target and effector cells, and to address the questions outlined above.
Materials and methods

Cells and antibodies
The B-lymphoma cell line SKW6.4 was provided by PH Krammer (DKFZ, Heidelberg, Germany), the T-cell line Jurkat by D Schendel (GSF Research Center for Environment and Health, Munich, Germany). The mouse myeloma cell line Sp2/0-Ag14 was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). All cells were kept in RPMI-1640 supplemented with 2 mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and 10% heat-inactivated fetal bovine serum (Sigma, Deisenhofen, Germany) in a humidified atmosphere containing 5% CO 2 .
Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood of healthy donors or leukemic patients by density gradient centrifugation (Biocoll Separation Solution, Biochrom, Berlin, Germany). Heparinized blood samples from patients with chronic lymphocytic leukemia were kindly provided by H Salih (Department of Internal Medicine II, University of Tü bingen, Tü bingen, Germany).
In some experiments, B cells were depleted from PBMC preparations using CD19 microbeads and an LD-depletion column in a Midi-MACS magnetic device and added back to depleted cultures to define more precisely the minimal number of cells required for the r2820-mediated induction of T-cell proliferation. T cells were enriched by positive selection with CD4 and CD8 microbeads and an LS-column according to the manufacturer's instructions (Miltenyi Biotech, Bergisch Gladbach, Germany).
The 9E10 hybridoma producing an anti-myc-tag antibody was purchased from ATCC (Manassas, VA, USA). The antibody was purified from hybridoma supernatant by protein A affinity chromatography.
Construction, production and purification of r2820
The recombinant phage antibody system (RPAS, Pharmacia Biotech, Freiburg, Germany) was used for isolation of a monospecific scFv-single-chain variant of the parental CD28 antibody 9.3 as described. 6 The scFv with specificity for human CD20 was generated by overlapping PCR using the published sequence of the V H -and V L -domains of the CD20 antibody 2H7. 9 These domains were linked by a glycin-serine linker (G 4 S) 3 , flanked with a BspEI and SpeI restriction site, respectively and inserted in-frame into an expression vector for bispecific antibodies described earlier. For production of the r2820 protein, the plasmid was linearized with AhdI and transfected by electroporation (230 V, 975 mF) into Sp2/0-Ag14 myeloma cells. Transfected cells were selected in RPMI containing 1 mg/ml G418 (Invitrogen, Karlsruhe, Germany) and subsequently cultured in triple flasks (Nunc, Wiesbaden, Germany). Cell culture supernatant was collected and passed over a protein L column purchased from Perbio Science (Bonn, Germany). The r2820 antibody was eluted from the column using 0.1 M glycine buffer at pH 3. The eluate was dialysed against PBS, filtered with a 0.22 mM filter and stored at 4 1C.
In addition to the bispecific single-chain antibody, a bispecific F(ab 0 ) 2 -fragment with identical specificities (2H7 Â 9.3) was constructed by chemical hybridization of TNB-modified Fab fragments as described. Briefly, parental antibodies were digested by pepsin and modified using Ellman's reagent (5, 5 0 -dithio-bis(2-nitrobenzoic acid). One of the modified antibodies was then reduced and mixed with the unreduced partner for hybridization. Reformation of the disulfide bridges in the hinge region was monitored spectrophotometrically. 10 Modified and hybridized Fab fragments respectively, were purified by gel filtration (see section Protein analysis).
Protein analysis
Analytical and preparative gel filtration was performed on Superdex200 PC3.2/30 and high load 16/60 columns, respectively (GE Healthcare, Mü nchen, Germany). Proteins were also analyzed by SDS-PAGE using gels containing 10% polyacrylamide (Roth, Karlsruhe, Germany). In the case of r2820, analysis by both methods is particularly important as the multimeric variants of this protein are destroyed by the denaturing conditions of the SDS-PAGE and thus are detectable only by gel filtration.
Flow cytometry
To determine the binding avidity of r2820, cells expressing CD28 (Jurkat) and CD20 (SKW6.4), respectively, were incubated with the antibody at various concentrations. Cells were then washed, incubated with the mouse anti-myc-tag antibody 9E10, washed again and stained with phycoerythrin (PE)-labelled F(ab 0 ) 2 fragments of goat anti-mouse IgG (Dianova, Hamburg, Germany). This antibody was also used for the detection of parental mouse antibody to CD28. The chimeric CD20 antibody (2H7-IgG1) was detected by a PE-labelled F(ab 0 ) 2 -fragment against human IgG (Dianova). Flow cytometry analysis was performed using a FACSCalibur equipped with CellQuest software (Becton Dickinson, San Jose, CA, USA).
T-cell activation
PBMCs (10 5 in 100 ml) were incubated with different antibody concentrations. In some experiments, B-cells were depleted from PBMCs using MACS beads as described above. During the last 16 h of a 4-day incubation period, 3 H-thymidine was added (18.5 kBq per well). All experiments were performed in 96-well plates as triplicates. Cells were harvested on a filtermate and radioactivity was determined in a scintillation counter (MicroBeta, Wallac, Finland). In some experiments, Rituximab (Roche Pharma, Basel, Switzerland), a therapeutic antibody directed to CD20, was used to block the proliferation induced by r2820. To measure cytokine release during T-cell activation, supernatant was obtained from cells at different time points after starting the assay and tested for IL-2 content using a human IL-2-ELISA kit (BD Biosciences, Heidelberg, Germany) according to the manufacturer's instructions. All ELISA experiments were performed in F96 Maxisorp plates (Nunc, Roskilde, Denmark) as triplicates.
Tumor-cell killing
PBMCs of normal donors were incubated for 5 days with SKW6.4 lymphoma cells at an E/T-ratio of 25:1 in the presence of the r2820 antibody. The chemically hybridized bsF(ab 0 ) 2 -fragment 2H7 Â 9.3 and the bispecific single-chain antibody r28M served as controls. In this type of experiment, T-cell activation led to an increase in effector cell numbers during the assay. Thus, at termination of the experiment, the total number of remaining, viable CD20-positive lymphoma cells was determined in treated as well as untreated control cultures. To this end, cells were counted in a Neubauer chamber, stained with a phycoerythrin-labelled anti-CD20 IgG1 (DAKO, Denmark) and the percentage of CD20-positive SKW6. Alternatively, cytotoxicity towards lymphoma cells was determined after incubation of PBMCs of healthy donors with
Killing of lymphoma cells with bispecific CD28 antibodies T Otz et al various amounts of r2820 using r28M as a negative control. After 2 days of incubation with the antibodies, 51 Cr-labelled target cells (SKW6.4, Raji and chronic lymphocytic leukemia (CLL) cells, respectively) were added to the PBMCs at an effector/target ratio of 50:1 and supernatant was harvested after 4 and 20 h. Cytotoxicity was determined according to the standard formula: %specific 51 Cr-release ¼ (experimental releaseÀspontaneous release)/(total releaseÀspontaneous release) Â100. Spontaneous and total release were determined by incubating target cells in a medium with and without 10% Triton X-100, respectively. Labelling of SKW6.4-and Raji-cells was performed in normal culture medium containing 50 mCi/ml of sodium chromate 51 Cr (Hartmann Analytic GmbH, Braunschweig, Germany). CLL cells of different donors were labelled in 50 mM Tris buffer pH 7.4 containing 300 mM NaCl, 1mM Na 2 PO 4 , 10 mM KCl and 100 mCi/ml of 51 Cr as described by Cemerlic et al.
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Results
Characterization of the r2820 single-chain molecule Figure 1a shows that the material eluted from protein L is homogeneous upon analysis by SDS-PAGE. The single band around 60 kDa is in good agreement with the calculated molecular weight of the bispecific single-chain antibody (57 kDa). In marked contrast, gel filtration reveals that a large proportion of the material forms multimers with molecular weights of up to approximately 220 kDa (Figure 1b) . Obviously, these aggregates are degraded during SDS treatment. These observations are similar to those reported previously for the bispecific r28M molecule which forms stable dimers. 6 Material from size exclusion chromatography was pooled as indicated in Figure 1b and used for further analysis (see Figure 2b) .
To test the binding activity of both parts of the molecule the r2820 antibody as well as the parental antibodies used for its construction, 2H7 and 9.3, were titrated on CD28-positive Jurkat cells and CD20-positive SKW6.4 cells, respectively. r2820 binds to both antigens, albeit with a quite different avidity. Binding to CD20 is considerably weaker than to CD28. The same holds true if binding of the parental antibodies, 2H7 and 9.3, is compared (Figures 1c and d) . Thus the inferior binding of r2820 to CD20 appears to be because of a corresponding inferior binding of the parental antibody rather than to an unfavorable folding of the CD20 antibody within the single-chain format. One should note, however, that direct comparability of binding data for r2820 and the parental antibodies, respectively, is limited, as for the detection of the bispecific single-chain reagent an anti-myc antibody had to be used.
r2820-induced T-cell activation in PBMC cultures of healthy donors
When isolated PBMCs from healthy donors were incubated for 4 days with the bispecific single-chain antibody r2820, a vigorous activation of autologous T cells was induced as measured by 3 H-thymidine uptake. In contrast, a bispecific F(ab 0 ) 2 -fragment with identical specificities as well as the supraagonistic single-chain antibody r28M, targeting NG2 rather than CD20, were ineffective. Proliferation induced by r2820 was as pronounced as that obtained with an optimal mitogenic dose of Killing of lymphoma cells with bispecific CD28 antibodies T Otz et al the panclonal T-cell activator phytohemagglutinin (Figure 2a) . Figure 2b demonstrates that the mitogenic activity of r2820 depends largely on its multimerization state, the multimeric version in pool 1 (Figure 1b ) being approximately 20 times more active than the largely monomeric material in pool 2. These results show that supra-agonistic activity relies on the singlechain format of the bispecific construct with its tendency to form multimers. Furthermore, it depends on the presence of the target antigen CD20 as the bispecific single-chain antibody targeting NG2 rather than CD20 was not active. We reasoned that in the experiments described, normal, autologous CD20-positive B cells contained in the PBMC preparations serve as target cells, which bind the bispecific construct. To prove this hypothesis, B cells were depleted from PBMC preparations and added back in defined numbers. Figure 2c shows that at least 20 000 B cells per well are required to restore r2820-mediated T-cell proliferation under the experimental conditions used (100.000 B-cell depleted PBMCs per well in 100 ml medium). A complete inhibition of T-cell activation could also be observed by blocking the CD20 molecules with an excess (10 mg/ml) of the anti-CD20 antibody Rituxan, which crossreacts with the epitope recognized by 2H7, the CD20 antibody used for construction of r2820 (Figure 2a ). When we measured the IL2-release in cell culture supernatants of PBMCs rather than 3 H-thymidine uptake, similar observations were made: If PBMCs were cultured with r2820, marked release of this index cytokine was observed which peaked after 1-2 days of stimulation. In contrast, if r28M was added or if B-cell-depleted PBMCs were used no significant IL-2 release was detected (Figure 2d ). Taken together, these results demonstrate that r2820 mediates potent activation of T cells through CD28 in an autologous and target cell-restricted setting, that is, if the antibody is bound to autologous CD20 þ B cells.
r2820-induced T-cell activation in PBMC cultures of CLL patients
PBMCs isolated from CLL patients consist mainly of leukemic cells of the B-cell lineage and the proportion of normal T cells is usually less than 10%. Therefore it was not surprising that nearly no T-cell activation could be observed after treating such 'CLL-PBMC's with r2820. However, if T cells were enriched by positive selection on MACS beads and added back in defined amounts to the CLL-PBMCs, T-cell proliferation was induced. At a threefold excess of T cells the extent of proliferation was comparable to that observed with normal PBMCs, but more antibody was required to achieve this effect (Figures 3 and 2a) . This is most likely due to the well-established functional deficits of the T cells of CLL patients, for example, decreased expression of CD28 12 or its abnormal expression kinetics during stimulation. 13 
Killing of tumor cells by r2820-activated PBMCs
To determine whether T-cell activation induced by r2820 results in tumor-cell killing, PBMCs from various healthy donors were (Figure 4) . In one of the three experiments a moderate proliferation of lymphoma cells was observed upon incubation with the control antibody r28M, resulting in a negative percentage of killing. The bispecific F(ab 0 ) 2 -fragment with CD20 Â CD28 specificity had a marginal activity in two of the three experiments.
To further characterize the cytolytic potential of r2820-activated PBMCs, we incubated the PBMCs of different healthy donors with various concentrations of the bispecific antibody. After 2 days, 51 Cr-labelled target cells, cultured lymphoma cells as well as CLL-cells, were added to the r2820-treated PBMCs. Cytotoxicity was determined and compared with that exerted by PBMCs incubated with the control antibody r28M, which targets the unrelated NG2 protein on melanoma cells. Figure 5 shows that both lymphoma cell lines, SKW6.4 and Raji, are effectively killed after 4 h of incubation with PBMCs activated by r2820 but not by those PBMCs incubated with r28M. The CLL cells of three different donors with leukocyte counts between 20 000 and 60 000 per ml were more difficult to label and were clearly more resistant towards killing by activated PBMCs. After 4 h no cytolytic effects were observed. After 20 h however, killing by the r2820-stimulated PBMCs was clearly detectable. In all experiments performed, killing by r2820-activated PBMCs was clearly superior to that obtained with cells incubated with the r28M control antibody. Negative values for specific 51 Cr release (Figure 5c ) result from the fact that the addition of untreated PBMCs to relatively resistant CLL cells may lead to a decrease of spontaneous release rates.
Discussion
We demonstrated earlier that r28M, a recombinant bispecific single-chain antibody directed to a NG2 and the costimulatory CD28 molecule on T cells induced T-cell activation which was dependent on the presence of tumor cells and resulted in tumorcell killing. [6] [7] [8] This activity was unexpected as an isolated CD28 stimulus by a conventional CD28 antibody should not induce T-cell activation and the CD28 antibody contained in r28M does not belong to the particular class of 'superagonistic' antibodies described by Tacke et al.
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In this study, we exchanged the NG2-targeting part of r28M with a single-chain antibody directed to the B-cell-associated antigen CD20. We found that in marked contrast to a bispecific F(ab 0 ) 2 fragment with identical specificities, the r2820 single-chain molecule leads to a pronounced proliferation of autologous T-cells within the PBMCs of healthy donors. In the absence of CD20 þ target cells or after blocking the CD20-molecules with the anti-CD20 antibody Rituxan, T-cell activation could not be observed. Obviously, in these experiments, normal B cells serve as target cells expressing CD20. The activity of the bispecific single-chain antibody was largely mediated by multimeric versions (dimers and most likely quadrumers) of the molecule. These results confirm that the previously described phenomenon of a target cell-restricted, supra-agonistic CD28 stimulation using the bispecific singlechain antibody r28M, is not a peculiar property of the antibodies contained in this particular molecule. Rather, the phenomenon seems to be robust and most likely attributable to the wellestablished tendency of bispecific single-chain molecules (bi-scFv) to form multimers. In the case of bi-scFv binding to CD28, these multimers obviously allow for a supra-agonistic stimulation of the CD28 molecule, which circumvents the need of a stimulus through the specific T-cell antigen receptor.
If clinical application is envisaged, procedures are required that allow production of defined and stable multimers of the bispecific single-chain molecules. For r28M, we have already developed such procedures, including the use of high salt buffers during multistep purification. It is likely that these Killing of lymphoma cells with bispecific CD28 antibodies T Otz et al techniques will be applicable to r2820. As it stands, r2820, isolated by a convenient one step protein L purification procedure, remains active for at least several weeks if stored in PBS at 4 1C.
It is of particular importance that, effective as it is, supraagonistic CD28 stimulation as described here is target cell restricted over a wide concentration range, that is, it is not induced if CD20-expressing target cells are absent. Obviously, this is a fundamental difference to TGN1412, a monospecific 'superagonistic' CD28 antibody. When injected into six healthy volunteers, this reagent induced systemic T-cell activation and a severe cytokine release syndrome. 5 In principle, such side effects should be avoidable by bispecific antibodies, if indeed the T-cell activation induced is target cell restricted in vivo. On the other hand, if target antigens are 'systemically expressed', as in the case of CD20 or CD19, systemic T-cell activation with concomitant cytokine release may take place, even if the activation is target cell restricted in the sense described above. The pronounced IL-2 release observed after incubation of normal PBMCs with the r2820 antibody illustrates this problem. Thus, the danger of side effects upon in vivo application appears to be larger for r2820 than for r28M. In general, we feel that caution is needed if the antigen chosen for targeting by potentially mitogenic bispecific antibodies is systemically expressed rather than locally confined.
If PBMCs from CLL patients rather than from healthy volunteers were used, r2820 failed to induce T-cell activation unless autologous T cells were added to reconstitute a normal ratio of B-cell targets and T-cell effectors. However, the doses of r2820 required for induction of T-cell proliferation were higher if CLL-PBMCs rather than normal PBMCs were used. It is well known that immunoregulatory abnormalities 15 and an abnormal distribution of subtypes [16] [17] [18] lead to a functional impairment of T cells in these patients. In particular, it has been described that CD28 expression on T cells from CLL patients is reduced 12 and that loss of CD28 during short-term culture of those cells in IL-2 is more pronounced than in normal T cells. 13 As far as the target antigen CD20 is concerned, we did not find a substantial reduction of CD20 expression on the CLL cells used for the current or previous experiments, respectively. 19 Thus, we think that the decreased response of T cells within the PBMCs of CLL patients towards stimulation with r2820 is best explained by the well-documented deficits of such cells as discussed above. We cannot rule out, however, that suppressive effects of the leukemic cells contributes to this phenomenon. In any case, T cells from normal donors as well as from patients do proliferate in the presence of autologous normal and malignant B cells, respectively. In addition, the experiments depicted in Figure 2 demonstrate T-cell activation by r2820 bound to normal autologous B cells. Taken together, these findings rule out that the allogeneic nature of target and effector cells contribute significantly to the phenomenon of supra-agonistic CD28 stimulation exerted by the bispecific r2820 antibody.
Once activated, T cells should be capable of killing tumor cells. In our experiments, r2820-induced killing of SKW6.4 lymphoma cells by normal PBMCs varied between 40 and 50% using PBMCs from different donors. Although clearly and reproducibly detectable, this is somewhat less impressive than the killing of melanoma and glioblastoma cells observed in previous experiments using the bispecific r28M antibody. 6, 8 This may be because of the relatively low affinity of the CD20 scFv to its target antigen (Figure 1 ) when compared with the NG2-scFv contained in r28M. 6 In subsequent experiments we noticed that killing is more pronounced if 51 Cr-labelled target cells are added to PBMCs after 2 days of stimulation with the r2820 antibody. Under these conditions, we were able to demonstrate killing of different cultured lymphoma-as well as of CLL-cells. Clearly however, the latter cells turned out to be considerably more resistant. This may apply to T cell-induced as well as NK cellmediated killing. With respect to the interaction of these cells, we have demonstrated earlier that cytokines produced by CD28-stimulated T cells activate NK cells, which then significantly contribute to tumor-cell lysis. 6, 8 In general, insufficient and costly production of bispecific antibodies using conventional cell culture technology has severely hampered the clinical evaluation of these reagents. Expression of these molecules can be improved using transgenic animals, an approach that we pursued previously for r28M. Rearranged V H and V L genes coding for this molecule were introduced into fertilized rabbit oocytes and bovine fetal fibroblasts to generate transgenic rabbits and cloned transgenic calves, respectively. The protein, purified from the serum of these animals, was active in T-cell activation and tumor-cell killing and the concentration in the serum of transgenic cows exceeded that obtained in the cell culture supernatant by a factor of fifty. 7, 8 In principle, this successful 'gene farming' approach should be applicable to similar bi-scFv, such as r2820.
In conclusion, supra-agonistic, selective CD28 stimulation with bispecific single-chain antibodies seems to be an attractive and feasible approach for experimental tumor therapy.
